| Jun 27 |
What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks with Highest Upside Potential?
|
| Jun 27 |
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
|
| Jun 25 |
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
|
| Jun 17 |
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
|
| Jun 14 |
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
|
| Jun 14 |
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
|
| Jun 7 |
Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound?
|
| May 22 |
EVP, Chief Financial Officer Erick Lucera Sells 22,337 Shares of Editas Medicine Inc (EDIT)
|
